{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T01:26:27Z","timestamp":1791941187359,"version":"4.3.4"},"reference-count":0,"publisher":"Bioscientifica","issue":"1","content-domain":{"domain":["joe.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,7]]},"abstract":"<jats:p>\n                    The aim of this study is to investigate the long-term (9 months) effects of variable doses (200\/100 \u03bcg\/day) of\n                    <jats:sc>l<\/jats:sc>\n                    -selenomethionine on autoimmune thyroiditis (AIT) and the parameters affecting the success rate of this therapy. The present study was designed in three steps: (1) 88 female patients with AIT (mean age = 40.1 \u00b1 13.3 years) were randomized into two groups according to their initial serum TSH, thyroid peroxidase antibody (TPOAb) concentrations, and age. All the patients were receiving\n                    <jats:sc>l<\/jats:sc>\n                    -thyroxine to keep serum TSH \u22642 mIU\/l. Group S2 (\n                    <jats:italic>n<\/jats:italic>\n                    = 48, mean TPOAb = 803.9 \u00b1 483.8 IU\/ml) received 200 \u03bcg\n                    <jats:sc>l<\/jats:sc>\n                    -selenomethionine per day, orally for 3 months, and group C (\n                    <jats:italic>n<\/jats:italic>\n                    = 40, mean TPOAb = 770.3 \u00b1 406.2 IU\/ml) received placebo. (2) 40 volunteers of group S2 were randomized into two age- and TPOAb-matched groups. Group S22 (\n                    <jats:italic>n<\/jats:italic>\n                    = 20) went on taking\n                    <jats:sc>l<\/jats:sc>\n                    -selenomethionine 200 \u03bcg\/day, while others (group S21) lowered the dose to 100 \u03bcg\/day. (3) 12 patients of group S22 (group S222) went on taking\n                    <jats:sc>l<\/jats:sc>\n                    -selenomethionine 200 \u03bcg\/day, while 12 patients of group S21 (S212) increased the dose to 200 \u03bcg\/day. Serum titers of TPOAb decreased significantly in group S2 (26.2%,\n                    <jats:italic>P<\/jats:italic>\n                    &lt; 0.001), group S22 (23.7%,\n                    <jats:italic>P<\/jats:italic>\n                    &lt; 0.01) and group S212 (30.3%,\n                    <jats:italic>P<\/jats:italic>\n                    &lt; 0.01). There were no significant changes in group C and group S222 (\n                    <jats:italic>P<\/jats:italic>\n                    &gt; 0.05). TPOAb titers increased significantly in group S21 (38.1%,\n                    <jats:italic>P<\/jats:italic>\n                    &lt; 0.01). A significant decrease in thyroglobulin antibody titers was only noted in group S2 (5.2%,\n                    <jats:italic>P<\/jats:italic>\n                    &lt; 0.01).\n                    <jats:sc>l<\/jats:sc>\n                    -selenomethionine substitution suppresses serum concentrations of TPOAb in patients with AIT, but suppression requires doses higher than 100 \u03bcg\/day which is sufficient to maximize glutathione peroxidase activities. The suppression rate decreases with time.\n                  <\/jats:p>","DOI":"10.1677\/joe.1.06661","type":"journal-article","created":{"date-parts":[[2006,7,12]],"date-time":"2006-07-12T15:45:00Z","timestamp":1152719100000},"page":"151-156","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-5","source":"Crossref","is-referenced-by-count":114,"title":["Selenium treatment in autoimmune thyroiditis: 9-month follow-up with variable doses"],"prefix":"10.1530","volume":"190","author":[{"given":"Omer","family":"Turker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamil","family":"Kumanlioglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inanc","family":"Karapolat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismail","family":"Dogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","container-title":["Journal of Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/joe.bioscientifica.com\/view\/journals\/joe\/190\/1\/1900151.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/joe.bioscientifica.com\/downloadpdf\/journals\/joe\/190\/1\/1900151.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:56:26Z","timestamp":1784555786000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/joe\/article\/190\/1\/151-156\/21033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7]]},"references-count":0,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.1677\/joe.1.06661","relation":{},"ISSN":["0022-0795","1479-6805"],"issn-type":[{"value":"0022-0795","type":"print"},{"value":"1479-6805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,7]]}}}